Yale scientists enlist most unlikely ally in efforts to treat glioblastoma

Yale scientists enlist most unlikely ally in efforts to treat glioblastoma

High intensity interval training for 20 minutes provides greater neuroplasticity Unlike normal cells, a large percentage of cancer cells lack the ability to generate an innate immune response against invaders such as viruses. This has led cancer researchers to explore the use of viruses to combat a variety of cancers. Using viruses carries an obvious risk -- they can introduce potentially dangerous infections. To get around this problem, scientists, including van den Pol, have experimented with creating or testing chimeric viruses, or a combination of genes from multiple viruses. They have the ability to target cancer cells without harming patients. One of the seven genes of the Ebola virus that helps it avoid an immune system response also contributes to its lethality. This intrigued van den Pol. He and the study's first author, Xue Zhang, also of Yale, used a chimeric virus containing one of gene from the Ebola virus -- a glycoprotein with a mucin-line domain (MLD). In wild-type Ebola virus, the MLD plays a role in hiding Ebola from the immune system. They injected this chimeric virus into the brains of mice with glioblastoma -- and found that the MLD helped selectively target and kill deadly glioblastoma brain tumors. (The team worked with the MLD glycoprotein, not with the full Ebola virus.) Van den Pol said MLD's beneficial effect appears to be that it protects normal cells from infection -- but not cancer cells, which lack the ability to mount an immune response to pathogens. A key factor may be that the virus with the glycoprotein MLD replicates less rapidly, potentially making it safer than viruses without the MLD part of the glycoprotein, he said. In theory, such a virus might be used in conjunction with surgery to eliminate glioblastoma tumors and help prevent a recurrence of cancer, he said. Source: Yale University Journal reference: Zhang, X., et al. (2020) Mucin-like domain of Ebola virus glycoprotein enhances selective oncolytic actions against brain tumors. Journal of Virology . doi.org/10.1128/JVI.01967-19 .



Also in Industry News

How to decide whether or not to start treatment for prostate cancer?
How to decide whether or not to start treatment for prostate cancer?

0 Comments

How to decide whether or not to start treatment for prostate cancer?

Read More

Analysis of the SARS-CoV-2 proteome via visual tools
Analysis of the SARS-CoV-2 proteome via visual tools

0 Comments

Analysis of the SARS-CoV-2 proteome via visual tools

Read More

$65m investment increases British Patient Capital’s exposure to life sciences and health technology
$65m investment increases British Patient Capital’s exposure to life sciences and health technology

0 Comments

$65m investment increases British Patient Capital’s exposure to life sciences and health technology

Read More